ABVX Key Statistics, Chart & Performance
The current stock price of ABVX is 122.12 USD. In the past month the price decreased by -11.73%. In the past year, price increased by 1905.25%.
ABVX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ABVX. When comparing the yearly performance of all stocks, ABVX is one of the better performing stocks in the market, outperforming 99.89% of all stocks.
ABVX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ABVX. ABVX has a bad profitability rating. Also its financial health evaluation is rather negative.
ABVX Financial Highlights
Over the last trailing twelve months ABVX reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS increased by 18.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -146.87% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABVX Forecast & Estimates
14 analysts have analysed ABVX and the average price target is 134.54 USD. This implies a price increase of 10.17% is expected in the next year compared to the current price of 122.12.
For the next year, analysts expect an EPS growth of -3.44% and a revenue growth 91.53% for ABVX
ABVX Ownership
ABVX Latest News, Press Relases and Analysis
About ABVX
Company Profile
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Company Info
ABIVAX SA-ADR
7-11 Boulevard Haussmann
Paris ILE-DE-FRANCE FR
Employees: 69
Phone: 33153830963
ABIVAX SA-ADR / ABVX FAQ
What does ABVX do?
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 69 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
What is the stock price of ABIVAX SA-ADR today?
The current stock price of ABVX is 122.12 USD. The price decreased by -1.22% in the last trading session.
Does ABIVAX SA-ADR pay dividends?
ABVX does not pay a dividend.
How is the ChartMill rating for ABIVAX SA-ADR?
ABVX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists ABVX stock?
ABVX stock is listed on the Nasdaq exchange.
Is ABIVAX SA-ADR (ABVX) expected to grow?
The Revenue of ABIVAX SA-ADR (ABVX) is expected to grow by 91.53% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
When does ABIVAX SA-ADR (ABVX) report earnings?
ABIVAX SA-ADR (ABVX) will report earnings on 2026-03-23, after the market close.